Replies to post #107 on ZymoGenetics (ZGEN)

[brooklyn137]

Correction, the milestones are not yet due, but will be when lamda proves itself.

[DewDiligence]

Your milestone figure includes $287M of clinical/regulatory milestones pertaining to non-HCV indications (presumably HBV) and $285M of sales-based milestones. It’s unlikely, IMO, that BMY would ever have had to pay ZGEN all of the latter or any of the former.

[newbie65]

oh..i didnt know that..i jsut saw that shareholder would get a bit over 9 bucks for each share..almost double from here. I see they moved up the bid and ask to the 9s.